** Shares of Pennsylvania-based medtech firm Neuronetics STIM.O rise 8.2% to $4.61
** Company forecasts 2025 revenue between $145 million and $155 million, above analysts' estimate of $93.55 million, according to data compiled by LSEG
** Company, which offers its NeuroStar device to treat major depressive disorder (MDD), posts Q4 revenue of $22.49 million, beating analysts' estimates of $19.63 million
** In the last 12 months, STIM has fallen 41.5%
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。